An mRNA influenza vaccine bests an inactivated quadrivalent flu vaccine against two different strains in phase 3 study.

The shingles vaccine not only offers protection against the painful viral infection, but a new study suggests that the two-dose shot also may slow the progression of dementia.

Influenza prevention with the cell-based quadrivalent vaccine (QIVc) was superior to the egg-based vaccine (QIVe) during the US 2022–2023 flu season.

A quadrivalent nucleoside-modified messenger RNA influenza vaccine met superiority criteria compared with a licensed inactivated vaccine.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...